This compound is a spirocyclic pharmaceutical intermediate featuring a hydroxy group, a methylsulfanyl substituent, and a tert-butyl ester protecting group. Its structure contains multiple aromatic and heterocyclic rings, and it is primarily used in the synthesis of kinase inhibitors for research and pharmaceutical manufacturing.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 2170746-97-9
Tert-butyl 4-methylsulfanyl-10-oxo-8-(trifluoromethylsulfonyloxy)spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
n.a
5-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarboxaldehyde
Pharmaceutical intermediate for kinase inhibitors
3-Amino-5-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile
Pharmaceutical intermediate for kinase inhibitors
2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
Pharmaceutical intermediate for kinase inhibitors
2-Bromo-5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazine
Pharmaceutical intermediate for kinase inhibitors
Trilaciclib Impurity 3
Pharmaceutical impurity reference standard
Benzyl (2S)-2-{8-aminoimidazo[1,5-a]pyrazin-3-yl}pyrrolidine-1-carboxylate
Pharmaceutical intermediate for impurity synthesis
Fmoc-Ile-Aib-OH
Peptide building block for synthesis
tert-butyl 8-hydroxy-4-methylsulfanyl-10-oxospiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate
WISYVWISRLRKNF-UHFFFAOYSA-N
CC(C)(C)OC(=O)N1CC2(CCCCC2)N3C(=C(C4=CN=C(N=C43)SC)O)C1=O
—